Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a Phase 2 Study

NCT04271384 is registered in ClinicalTrials.gov with Hospital Israelita Albert Einstein as lead sponsor.

NCT NCT04271384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04271384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a Phase 2 Study
Lead sponsor
Hospital Israelita Albert Einstein
Phase
Phase 2
Overall status
Completed
Start date
February 12, 2020
Completion date
November 15, 2023
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer stage i